Incannex commences DReAMzz study of IHL-42X for obstructive sleep apnea

Incannex Healthcare Inc.

All 14 clinical trial sites identified; site contracting underway; import/export permits secured.
Study is a crossover dose optimization to de-risk Phase III pathway for IHL-42X.
Previously reported Phase II RePOSA showed statistically significant AHI reductions and improved oxygenation.
FDA granted Fast Track designation for IHL-42X in OSA.
Manufacturing of clinical trial supply completed; global distribution partner onboarded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.